Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

The Effect of Bevacizumab on Corneal Neovascularization (BQ-1-08-ARVO)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Joao Nassaralla, Instituto de Olhos de Goiania
ClinicalTrials.gov Identifier:
NCT00797303
First received: November 22, 2008
Last updated: December 1, 2011
Last verified: November 2011
  Purpose

Eight patients with corneal neovascularization were treated with subconjunctival injection of 1.25 mg bevacizumab and had a follow-up of at least 2 months. All patients had persistent corneal neovascularization for at least 6 months unresponsive to other treatments. Patients were monitored by ophthalmic exam and anterior segment photography.


Condition Intervention Phase
Corneal Neovascularization
Drug: Bevacizumab
Phase 4

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Single Blind (Investigator)
Primary Purpose: Treatment
Official Title: The Effect of Bevacizumab on Corneal Neovascularization

Resource links provided by NLM:


Further study details as provided by Instituto de Olhos de Goiania:

Primary Outcome Measures:
  • The Effect of Bevacizumab on Corneal Neovascularization [ Time Frame: Compare the results ] [ Designated as safety issue: Yes ]
    Eight patients with corneal neovascularization were treated with subconjunctival injection of 1.25 mg bevacizumab and had a follow-up of at least 2 months. All patients had persistent corneal neovascularization for at least 6 months unresponsive to other treatments. Patients were monitored by ophthalmic exam and anterior segment photography


Enrollment: 8
Study Start Date: January 2006
Study Completion Date: November 2008
Primary Completion Date: July 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
A single intraoperative subconjunctival application of bevacizumab and 2 months follow-up
Drug: Bevacizumab
subconjunctival injection of 1.25 mg bevacizumab and had a follow-up of at least 2 months

Detailed Description:

To evaluate the effect of repeated subconjunctival bevacizumab (Avastin®, Roche, Rio de Janeiro, Brazil) on inflammatory corneal neovascularization.

Eight patients with corneal neovascularization were treated with subconjunctival injection of 1.25 mg bevacizumab and had a follow-up of at least 2 months. All patients had persistent corneal neovascularization for at least 6 months unresponsive to other treatments. Patients were monitored by ophthalmic exam and anterior segment photography.

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Corneal Neovascularization
  • Stable lesion

Exclusion Criteria:

  • Diabetes
  • Autoimmune diseases
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00797303

Sponsors and Collaborators
Instituto de Olhos de Goiania
Investigators
Study Chair: Belquiz A Nassaralla, PhD Instituto de Olhos de Goiânia
  More Information

No publications provided

Responsible Party: Joao Nassaralla, Clinical Professor, Instituto de Olhos de Goiania
ClinicalTrials.gov Identifier: NCT00797303     History of Changes
Other Study ID Numbers: BQ-1-08-ARVO
Study First Received: November 22, 2008
Last Updated: December 1, 2011
Health Authority: Brazil: National Health Surveillance Agency

Keywords provided by Instituto de Olhos de Goiania:
bevacizumab
cornea
neovascularization

Additional relevant MeSH terms:
Corneal Neovascularization
Neovascularization, Pathologic
Corneal Diseases
Eye Diseases
Metaplasia
Pathologic Processes
Bevacizumab
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Antineoplastic Agents
Growth Inhibitors
Growth Substances
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses

ClinicalTrials.gov processed this record on November 27, 2014